Biological
SYS6006
SYS6006 is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_4
2
67%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 42 (66.7%)
Trials by Status
completed133%
unknown133%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity
NCT07834073
not_yet_recruitingphase_1
SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors
NCT07622225
unknownphase_4
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
NCT05855408
Clinical Trials (3)
Showing 3 of 3 trials
NCT07834073Phase 4
Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity
NCT07622225Phase 1
SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors
NCT05855408Phase 4
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3